|
C15ORF41 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.6242562850266E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.00260000002184E-06 |
| Normal-vs-Stage3 |
3.75439679345391E-11 |
| Normal-vs-Stage4 |
2.13549955496717E-10 |
| Stage1-vs-Stage2 |
2.349800E-02 |
| Stage1-vs-Stage3 |
5.010200E-01 |
| Stage1-vs-Stage4 |
4.103600E-01 |
| Stage2-vs-Stage3 |
1.718050E-01 |
| Stage2-vs-Stage4 |
2.401200E-01 |
| Stage3-vs-Stage4 |
8.316000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.75599999985288E-07 |
| Normal-vs-Asian |
1.6704004845991E-10 |
| Caucasian-vs-AfricanAmerican |
8.878800E-01 |
| Caucasian-vs-Asian |
8.462600E-01 |
| AfricanAmerican-vs-Asian |
8.104800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.40367750545556E-12 |
| Normal-vs-Female |
1.62436730732907E-12 |
| Male-vs-Female |
6.068200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
1.79890000007177E-07 |
| Normal-vs-Age(81-100Yrs) |
2.092100E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.943800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.601800E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.144000E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.119500E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.138410E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.817800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.095800E-01 |
| Classical-VS-Follicular |
1.405800E-01 |
| Classical-VS-Other |
3.751400E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
3.581200E-01 |
| Tall-VS-Other |
5.242400E-01 |
| Tall-VS-Normal |
1.38720000042447E-07 |
| Follicular-VS-Other |
2.878600E-01 |
| Follicular-VS-Normal |
6.2491999996972E-07 |
| Other-VS-Normal |
1.795630E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.8928864272475E-14 |
| Normal-vs-N1 |
3.21853654838833E-13 |
| N0-vs-N1 |
4.221800E-01 |
|
|
